Dr. Reddy's Laboratories Limited (RDY)
Healthcare · NYQ
Price as at 1 Oct 2026, 00:16 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Dr. Reddy's Laboratories Limited trades at $12.62, which is 59% above the $5.17 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 56 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 23.9 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
RDY dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.083 | 1 |
| 2025 | $0.091 | 1 |
| 2024 | $0.096 | 1 |
| 2023 | $0.195 | 2 |
| 2022 | $0.153 | 2 |
| 2021 | $0.136 | 2 |
| 2020 | $0.066 | 1 |
| 2019 | $0.057 | 1 |
| 2018 | $0.059 | 1 |
| 2017 | $0.062 | 1 |
| 2016 | $0.059 | 1 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
RDY earnings and analyst estimates
Recommendation mix, 5 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
RDY passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$106.46M · 0.1% of book
- Marshall Wace, MARSHALL WACE, LLP$29.35M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$8.01M · 0.0% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$7.09M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$6.79M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
RDY peers
The largest companies in the same industry (Drug Manufacturers - Specialty & Generic), then in the same sector.
- TKPHF Takeda Pharmaceutical Company Limited
- GALDY Galderma Group AG
- JHPCY JHPCY
- HLNCF Haleon plc
- TEVA Teva Pharmaceutical Industries Limited
- UTHR United Therapeutics Corporation
- VTRS Viatris Inc.
- NBIX Neurocrine Biosciences, Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Dr. Reddy's Laboratories Limited (RDY) undervalued?
Against our fair value estimate of $5.17, RDY at $12.62 is 59% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own RDY?
9 of the institutions we track reported a position in RDY in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is RDY's P/E ratio?
RDY trades at 23.9 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Dr. Reddy's Laboratories Limited (RDY) pay a dividend?
Yes. Dr. Reddy's Laboratories Limited yields 0.63% at the current share price. It has paid $0.083 per share over the trailing twelve months. It has paid a dividend in each of the last 25 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its RDY data?
Fundamentals for RDY come from company filings and exchange data, as listed on NYQ; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 00:16 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for RDY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.